Please ensure Javascript is enabled for purposes of website accessibility
Accessibility Menu
Fate Therapeutics Stock Quote

Fate Therapeutics (NASDAQ: FATE)

$5.04
(-4.4%)
-$0.23
Price as of April 18, 2024, 4:00 p.m. ET

Fate Therapeutics Return vs. S&P

1 Year 5 Year 5 Year Annualized Since IPO
FATE -20.75% -68.54% -20.63% -20%
S&P +20.88% +72.88% +11.56% +196%

Fate Therapeutics Company Info

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

News & Analysis

Valuation

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.